Self-aggregated nanoparticles based on amphiphilic poly(lactic acid)-grafted-chitosan copolymer for ocular delivery of amphotericin B

International Journal of Nanomedicine

Volumn 8, Issue , 2013, Pages 3715-3728

  Zhou, Wenjun ^a   Wang, Yuanyuan ^a   Jian, Jiuying ^a   Song, Shengfang ^a  

^a CHONGQING MEDICAL UNIVERSITY   (China)

Author keywords

Amphotericin B; Chitosan; Nanoparticles; Poly(lactic acid)

Indexed keywords

AMPHOTERICIN B; CHITOSAN LACTIC ACID COPOLYMER; COPOLYMER; NANOPARTICLE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIFUNGAL ACTIVITY; ARTICLE; CANDIDA ALBICANS; CHEMICAL STRUCTURE; CONTROLLED STUDY; DRUG DOSAGE FORM COMPARISON; DRUG PENETRATION; EYE IRRITATION; IN VITRO STUDY; IN VIVO STUDY; INFRARED SPECTROSCOPY; INTRAOCULAR DRUG ADMINISTRATION; MINIMUM INHIBITORY CONCENTRATION; NANOENCAPSULATION; NONHUMAN; PARTICLE SIZE; POLYMERIZATION; PROTON NUCLEAR MAGNETIC RESONANCE; SUSTAINED DRUG RELEASE; X RAY DIFFRACTION; ZETA POTENTIAL;

AMPHOTERICIN B; CHITOSAN; NANOPARTICLES; POLY(LACTIC ACID);

ACRYLIC RESINS; ADMINISTRATION, OPHTHALMIC; AMPHOTERICIN B; ANIMALS; ANTIFUNGAL AGENTS; CANDIDA; CELL SURVIVAL; CHITOSAN; CRYSTALLIZATION; DIFFUSION; DRUG COMPOUNDING; EYE INFECTIONS, FUNGAL; HYDROPHOBIC AND HYDROPHILIC INTERACTIONS; NANOCAPSULES; PARTICLE SIZE; RABBITS;

EID: 84884734426     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S51186     Document Type: Article

References (42)

1. Xie L, Zhong W, Shi W, Sun S. Spectrum of fungal keratitis in north China. Ophthalmology. 2006;113(11):1943-1948.
2. Das S, Suresh PK. Nanosuspension: a new vehicle for the improvement of the delivery of drugs to the ocular surface. Application to amphotericin B. Nanomedicine. 2011;7(2):242-247.
3. Morand K, Bartoletti AC, Bochot A, Barratt G, Brandely ML, Chast F. Liposomal amphotericin B eyedrops to treat fungal keratitis: physico-chemical and formulation stability. Int J Pharm. 2007;344(1-2): 150-153.
4. Kaur IP, Kakkar S. Topical delivery of antifungal agents. Expert Opin Drug Deliv. 2010;7(11):1303-1327.
5. Sahoo SK, Dilnawaz F, Krishnakumar S. Nanotechnology in ocular drug delivery. Drug Discov Today. 2008;13(3-4):144-151.
6. Eljarrat-Binstock E, Pe'er J, Domb AJ. New techniques for drug delivery to the posterior eye segment. Pharm Res. 2010;27(4):530-543.
7. Gaudana R, Jwala J, Boddu SH, Mitra AK. Recent perspectives in ocular drug delivery. Pharm Res. 2009;26(5):1197-1216.
8. Qu L, Li L, Xie H. Corneal and aqueous humor concentrations of amphotericin B using three different routes of administration in a rabbit model. Ophthalmic Res. 2010;43(3):153-158.
9. Liu Z, Li J, Nie S, Guo H, Pan W. Effects of transcutol P on the corneal permeability of drugs and evaluation of its ocular irritation of rabbit eyes. J Pharm Pharmacol. 2006;58(1):45-50.
10. Nagarwal RC, Kant S, Singh PN, Maiti P, Pandit JK. Polymeric nanoparticulate system: a potential approach for ocular drug delivery. J Control Release. 2009;136(1):2-13.
11. Pleyer U, Legmann A, Mondino BJ, Lee DA. Use of collagen shields containing amphotericin B in the treatment of experimental Candida albicans-induced keratomycosis in rabbits. Am J Ophthalmol. 1992;113(3):303-308.
12. Das S, Suresh PK, Desmukh R. Design of Eudragit RL 100 nanoparticles by nanoprecipitation method for ocular drug delivery. Nanomedicine. 2010;6(2):318-323.
13. Kaur IP, Rana C, Singh H. Development of effective ocular preparations of antifungal agents. J Ocul Pharmacol Ther. 2008;24(5):481-493.
14. Alonso MJ, Sanchez A. The potential of chitosan in ocular drug delivery. J Pharm Pharmacol. 2003;55(11):1451-1463.
15. de la Fuente M, Ravina M, Paolicelli P, Sanchez A, Seijo B, Alonso MJ. Chitosan-based nanostructures: a delivery platform for ocular therapeutics. Adv Drug Deliv Rev. 2010;62(1):100-117.
16. Enriquez de Salamanca A, Diebold Y, Calonge M, et al. Chitosan nanoparticles as a potential drug delivery system for the ocular surface: toxicity, uptake mechanism and in vivo tolerance. Invest Ophthalmol Vis Sci. 2006;47(4):1416-1425.
17. Paolicelli P, de la Fuente M, Sanchez A, Seijo B, Alonso MJ. Chitosan nanoparticles for drug delivery to the eye. Expert Opin Drug Deliv. 2009;6(3):239-253.
18. Sezer AD, Cevher E. Topical drug delivery using chitosan nano- and microparticles. Expert Opin Drug Deliv. 2012;9(9):1129-1146.
19. Elsaid N, Jackson TL, Gunic M, Somavarapu S. Positively charged amphiphilic chitosan derivative for the transscleral delivery of rapamycin. Invest Ophthalmol Vis Sci. 2012;53(13):8105-8111.
20. Zhou H, Liu X, Guo X, et al. Synthesis and characterization of amphiphilic chitosan derivatives as a nano-carrier for paclitaxel delivery. J Control Release. 2011; 152 Suppl 1:e124-e125.
21. Lassalle V, Ferreira ML. PLA nano- and microparticles for drug delivery: an overview of the methods of preparation. Macromol Biosci. 2007;7(6):767-783.
22. Xiao RZ, Zeng ZW, Zhou GL, Wang JJ, Li FZ, Wang AM. Recent advances in PEG-PLA block copolymer nanoparticles. Int J Nanomedicine. 2010;5:1057-1065.
23. Li G, Zhuang Y, Mu Q, Wang M, Fang Ye. Preparation, characterization and aggregation behavior of amphiphilic chitosan derivative having poly (L-lactic acid) side chains. Carbohydr Polym. 2008;72(1):60-66.
24. Zhang X, Zhu X, Ke F, et al. Preparation and self-assembly of amphiphilic triblock copolymers with polyrotaxane as a middle block and their application as carrier for the controlled release of Amphotericin B. Polymer. 2009;50(18):4343-4351.
25. Zhu X, Su M, Tang S, et al. Synthesis of thiolated chitosan and preparation nanoparticles with sodium alginate for ocular drug delivery. Mol Vis. 2012;18:1973-1982.
26. Wikler M. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing: Eighteenth Informational Supplement. Wayne: Clinical and Laboratory Standards Institute. 2008.
27. Li J, Kong M, Cheng XJ, et al. Preparation of biocompatible chitosan grafted poly(lactic acid) nanoparticles. Int J Biol Macromol. 2012;51(3): 221-227.
28. Bhattarai N, Ramay HR, Chou SH, Zhang M. Chitosan and lactic acid-grafted chitosan nanoparticles as carriers for prolonged drug delivery. Int J Nanomedicine. 2006;1(2):181-187.
29. Amidi M, Mastrobattista E, Jiskoot W, Hennink WE. Chitosan-based delivery systems for protein therapeutics and antigens. Adv Drug Deliv Rev. 2010;62(1):59-82.
30. Agnihotri SA, Mallikarjuna NN, Aminabhavi TM. Recent advances on chitosan-based micro- and nanoparticles in drug delivery. J Control Release. 2004;100(1):5-28.
31. Bihari P, Vippola M, Schultes S, et al. Optimized dispersion of nanoparticles for biological in vitro and in vivo studies. Part Fibre Toxicol. 2008;5:14.
32. de Campos AM, Diebold Y, Carvalho EL, Sanchez A, Alonso MJ. Chitosan nanoparticles as new ocular drug delivery systems: in vitro stability, in vivo fate, and cellular toxicity. Pharm Res. 2004;21(5):803-810.
33. Wadhwa S, Paliwal R, Paliwal SR, Vyas SP. Hyaluronic acid modified chitosan nanoparticles for effective management of glaucoma: development, characterization, and evaluation. J Drug Target. 2010;18(4):292-302.
34. Stahl U, Willcox M, Stapleton F. Osmolality and tear film dynamics. Clin Exp Optom. 2012;95(1):3-11.
35. Zhou W, Zhao M, Zhao Y, Mou Y. A fibrin gel loaded with chitosan nanoparticles for local delivery of rhEGF: preparation and in vitro release studies. J Mater Sci Mater Med. 2011;22(5):1221-1230.
36. Zhou S, Deng X, Li X. Investigation on a novel core-coated microspheres protein delivery system. J Control Release. 2001;75(1-2):27-36.
37. Amescua G, Miller D, Alfonso EC. What is causing the corneal ulcer? Management strategies for unresponsive corneal ulceration. Eye (Lond). 2012;26(2):228-236.
38. Brajtburg J, Powderly WG, Kobayashi GS, Medoff G. Amphotericin B: current understanding of mechanisms of action. Antimicrob Agents Chemother. 1990;34(2):183-188.
39. O'Day DM, Head WS, Robinson RD, Clanton JA. Corneal penetration of topical amphotericin B and natamycin. Curr Eye Res. 1986;5(11): 877-882.
40. Tuli SS. Fungal keratitis. Clin Ophthalmol. 2011;5:275-279.
41. Lawrence MS, Miller JW. Ocular tissue permeabilities. Int Ophthalmol Clin. 2004;44(3):53-61.
42. De Campos AM, Sanchez A, Alonso MJ. Chitosan nanoparticles: a new vehicle for the improvement of the delivery of drugs to the ocular surface. Application to cyclosporin A. Int J Pharm. 2001;224(1-2):159-168.